193 related articles for article (PubMed ID: 21102648)
1. Lorcaserin--not a new weapon in the battle with appetite.
Halford JC
Nat Rev Endocrinol; 2010 Dec; 6(12):663-4. PubMed ID: 21102648
[No Abstract] [Full Text] [Related]
2. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
4. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
5. New medications for weight loss.
Murfin M
JAAPA; 2012 Dec; 25(12):59-60. PubMed ID: 23600006
[No Abstract] [Full Text] [Related]
6. Pharmacologic therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2010 Mar; 39(1):69-79. PubMed ID: 20202580
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacotherapy for obesity.
Srivastava G; Apovian CM
Nat Rev Endocrinol; 2018 Jan; 14(1):12-24. PubMed ID: 29027993
[TBL] [Abstract][Full Text] [Related]
8. 5-HT(2C) receptor agonists and the control of appetite.
Halford JC; Harrold JA
Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
[TBL] [Abstract][Full Text] [Related]
9. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252
[TBL] [Abstract][Full Text] [Related]
10. Efficacy comparison of medications approved for chronic weight management.
Kumar RB; Aronne LJ
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
[TBL] [Abstract][Full Text] [Related]
11. Lorcaserin approval in the United States: paving the way?
Pedersen SD; Astrup A
Endocrinol Nutr; 2012 Nov; 59(9):521-2. PubMed ID: 22939712
[No Abstract] [Full Text] [Related]
12. Drug management of obesity--efficacy versus safety.
Astrup A
N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
[No Abstract] [Full Text] [Related]
13. ACS chemical neuroscience molecule spotlight on Qnexa.
Mercer SL
ACS Chem Neurosci; 2011 Apr; 2(4):183-4. PubMed ID: 22778866
[TBL] [Abstract][Full Text] [Related]
14. Anti-obesity drugs.
Proietto J
Med J Aust; 1998 Apr; 168(8):409-12. PubMed ID: 9594954
[No Abstract] [Full Text] [Related]
15. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
16. Horizons in the Pharmacotherapy of Obesity.
Arch JR
Curr Obes Rep; 2015 Dec; 4(4):451-9. PubMed ID: 26346394
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
Toubro S
Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
[No Abstract] [Full Text] [Related]
18. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
19. Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.
Lu CW; Chang CJ; Yang YC; Lin WY; Huang KC
Obes Res Clin Pract; 2018 Jul; 12(5):465-471. PubMed ID: 30033356
[TBL] [Abstract][Full Text] [Related]
20. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
